美国 - 英文 - NLM (National Library of Medicine)

shantou youjia e-commerce co., ltd. - olive oil (unii: 6uyk2w1w1e) (olive oil - unii:6uyk2w1w1e), mentha piperita leaf (unii: a389o33lx6) (mentha piperita leaf - unii:a389o33lx6), dimethicone (unii: 92ru3n3y1o) (dimethicone - unii:92ru3n3y1o), rosemary (unii: ij67x351p9) (rosemary - unii:ij67x351p9) -

美国 - 英文 - NLM (National Library of Medicine)

chi research, inc. - cinnamon bark oil (unii: xe54u569ec) (cinnamon bark oil - unii:xe54u569ec), clove oil (unii: 578389d6d0) (clove oil - unii:578389d6d0), eucalyptus oil (unii: 2r04oni662) (eucalyptus oil - unii:2r04oni662), lemon oil (unii: i9gro824ll) (lemon oil - unii:i9gro824ll), rosemary oil (unii: 8lgu7vm393) (rosemary oil - unii:8lgu7vm393) - cinnamon bark oil 12 [hp_c] in 1 ml - for temporary relief of symptoms associated with cellular detox. for temporary relief of symptoms associated with cellular detox.

美国 - 英文 - NLM (National Library of Medicine)

chi research, inc. - cinnamon bark oil (unii: xe54u569ec) (cinnamon bark oil - unii:xe54u569ec), clove oil (unii: 578389d6d0) (clove oil - unii:578389d6d0), eucalyptus oil (unii: 2r04oni662) (eucalyptus oil - unii:2r04oni662), lemon oil (unii: i9gro824ll) (lemon oil - unii:i9gro824ll), rosemary oil (unii: 8lgu7vm393) (rosemary oil - unii:8lgu7vm393) - for temporary relief of symptoms associated with cellular detox. for temporary relief of symptoms associated with cellular detox.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.3mg;  ; conjugated estrogens 0.3mg (includes 3% overage); conjugated estrogens 0.3mg - tablet - 0.3 mg - active: conjugated estrogens 0.3mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opaglos clear 98z19173 opalux green shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.3mg (includes 3% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode white s-8-28905 opalux green shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.3mg excipient: carnauba wax hyprolose hypromellose     lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose   opacode white ns-78-18011 opadry green 15b21511 sucrose

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - conjugated estrogens 0.625mg;  ; conjugated estrogens 0.625mg (includes 3% overage); conjugated estrogens 0.625mg - tablet - 0.625 mg - active: conjugated estrogens 0.625mg   excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opaglos clear 98z19173 shellac stearic acid sucrose titanium dioxide urethane dimethacrylate luting resin active: conjugated estrogens 0.625mg (includes 3% overage) excipient: calcium sulfate carnauba wax glyceryl mono-oleate lactose monohydrate macrogol 20000 magnesium stearate methylcellulose microcrystalline cellulose opacode opalux maroon as-3910 shellac stearic acid sucrose titanium dioxide active: conjugated estrogens 0.625mg excipient: carnauba wax hyprolose hypromellose     lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose   opacode white ns-78-18011 opadry maroon 03b16083 sucrose

美国 - 英文 - NLM (National Library of Medicine)

a-s medication solutions - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg - limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered premarin therapy is contraindicated in individuals with any of the following conditions: premarin should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. premarin should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectable amounts of estrogens have been identified in the breast milk of mothers receiving estrogen-alone therapy. caution should be exercised when premarin is administered to a nursing woman. estrogen therapy has been used for the induction of puberty in adolescents with some forms of pubertal delay. safety and effectiveness in pediatric patients have not otherwise been established. large and repeated doses of estrogen over an extended time period have been shown to accelerate epiphyseal closure, which could result in short stature if treatment is initiated before the completion of physiologic puberty in normally developing children. if estrogen is administered to patients whose bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended during estrogen administration. estrogen treatment of prepubertal girls also induces premature breast development and vaginal cornification, and may induce vaginal bleeding. in boys, estrogen treatment may modify the normal pubertal process and induce gynecomastia. there have not been sufficient numbers of geriatric patients involved in studies utilizing premarin to determine whether those over 65 years of age differ from younger subjects in their response to premarin. the women's health initiative study in the whi estrogen-alone substudy (daily ce 0.625 mg-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.5)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg]), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.5)] . the women's health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.3), and clinical studies (14.6)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see warnings and precautions (5.3), and clinical studies (14.6)]. the effect of renal impairment on the pharmacokinetics of premarin has not been studied. the effect of hepatic impairment on the pharmacokinetics of premarin has not been studied.

美国 - 英文 - NLM (National Library of Medicine)

a-s medication solutions - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered premarin therapy is contraindicated in individuals with any of the following conditions: premarin should not be used during pregnancy [see contraindications (4)] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. premarin should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectable amounts of estrogens have been identified in the breast milk of mothers receiving estrogen-alone therapy. caution should be exercised when premarin is administered to a nursing woman. estrogen therapy has been used for the induction of puberty in adolescents with some forms of pubertal delay. safety and effectiveness in pediatric patients have not otherwise been established. large and repeated doses of estrogen over an extended time period have been shown to accelerate epiphyseal closure, which could result in short stature if treatment is initiated before the completion of physiologic puberty in normally developing children. if estrogen is administered to patients whose bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended during estrogen administration. estrogen treatment of prepubertal girls also induces premature breast development and vaginal cornification, and may induce vaginal bleeding. in boys, estrogen treatment may modify the normal pubertal process and induce gynecomastia. there have not been sufficient numbers of geriatric patients involved in studies utilizing premarin to determine whether those over 65 years of age differ from younger subjects in their response to premarin. the women's health initiative study in the whi estrogen-alone substudy (daily ce 0.625 mg-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.5)] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg]), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.5)] . the women's health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.3), and clinical studies (14.6)] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see warnings and precautions (5.3), and clinical studies (14.6)]. the effect of renal impairment on the pharmacokinetics of premarin has not been studied. the effect of hepatic impairment on the pharmacokinetics of premarin has not been studied.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

great grand care pty ltd - anemarrhena asphodeloides, quantity: 34.5 mg/g; phellodendron chinense, quantity: 34.5 mg/g; paeonia suffruticosa, quantity: 51.7 mg/g; alisma orientale, quantity: 51.7 mg/g; rehmannia glutinosa, quantity: 137.9 mg/g; cornus officinalis, quantity: 69 mg/g; dioscorea oppositifolia, quantity: 69 mg/g; wolfiporia cocos, quantity: 51.7 mg/g - granules - excipient ingredients: potato starch - traditionally used in chinese medicine to nourish yin/yin element/stratum ; traditionally used in chinese medicine to nourish/tonify/replenish kidney-yin

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

sun ten chinaherb co (aust) pty ltd - rehmannia glutinosa, quantity: 136.75 mg/g (equivalent: rehmannia glutinosa, qty 533.33 mg/g); wolfiporia cocos, quantity: 51.28 mg/g (equivalent: wolfiporia cocos, qty 200 mg/g); paeonia suffruticosa, quantity: 51.28 mg/g (equivalent: paeonia suffruticosa, qty 200 mg/g); cornus officinalis, quantity: 68.38 mg/g (equivalent: cornus officinalis, qty 266.67 mg/g); anemarrhena asphodeloides, quantity: 34.19 mg/g (equivalent: anemarrhena asphodeloides, qty 133.33 mg/g); alisma orientale, quantity: 51.28 mg/g (equivalent: alisma orientale, qty 200 mg/g); dioscorea oppositifolia, quantity: 68.38 mg/g (equivalent: dioscorea oppositifolia, qty 266.67 mg/g); phellodendron chinense, quantity: 34.19 mg/g (equivalent: phellodendron chinense, qty 133.33 mg/g) - granules - excipient ingredients: powdered cellulose; maize starch - traditionally used in chinese medicine to dispel/expel/disperse/clear fire ; traditionally used in chinese medicine to nourish yin/yin element/stratum ; traditionally used in chinese medicine to relieve irritability ; traditionally used in chinese medicine to decrease/reduce/relieve mild dizziness/vertigo

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

shen neng herbal medicines group pty ltd - anemarrhena asphodeloides, quantity: 6.73 mg (equivalent: anemarrhena asphodeloides, qty 25.9 mg); cornus officinalis, quantity: 21 mg (equivalent: cornus officinalis, qty 21 mg); rehmannia glutinosa, quantity: 26.86 mg (equivalent: rehmannia glutinosa, qty 103.4 mg); dioscorea oppositifolia, quantity: 51.7 mg (equivalent: dioscorea oppositifolia, qty 51.7 mg); wolfiporia cocos, quantity: 10.1 mg (equivalent: wolfiporia cocos, qty 38.8 mg); alisma orientale, quantity: 10.1 mg (equivalent: alisma orientale, qty 38.8 mg); paeonia suffruticosa, quantity: 6.71 mg (equivalent: paeonia suffruticosa, qty 25.8 mg); cornus officinalis, quantity: 7.974 mg (equivalent: cornus officinalis, qty 30.6999 mg); paeonia suffruticosa, quantity: 13 mg (equivalent: paeonia suffruticosa, qty 13 mg); phellodendron amurense, quantity: 6.73 mg (equivalent: phellodendron amurense, qty 25.9 mg) - pill - excipient ingredients: purified talc; maize starch - traditionally used in chinese medicine to dispel/expel/disperse/clear fire ; traditionally used in chinese medicine to nourish yin/yin element/stratum ; traditionally used in chinese medicine to relieve weariness/tiredness/fatigue/feeling of weakness ; traditionally used in chinese medicine to decrease/reduce/relieve excessive perspiration/sweating ; traditionally used in chinese medicine to helps decrease/reduce/relieve frequent need to urinate associated with mild anxiety ; traditionally used in chinese medicine to decrease/reduce/relieve sleeplessness